$3.04
2.56%
Nasdaq, Fri, Nov 01 2024
ISIN
US0021201035
Symbol
LIFE
Sector
Industry

aTyr Pharma, Inc. Target price 2024 - Analyst rating & recommendation

aTyr Pharma, Inc. Classifications & Recommendation:

Buy
100%

aTyr Pharma, Inc. Price Target

Target Price $21.29
Price $3.04
Potential
Number of Estimates 7
7 Analysts have issued a price target aTyr Pharma, Inc. 2025 . The average aTyr Pharma, Inc. target price is $21.29. This is higher than the current stock price. The highest price target is
$35.00 1,051.32%
register free of charge
, the lowest is .
A rating was issued by 7 analysts: 7 Analysts recommend aTyr Pharma, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the aTyr Pharma, Inc. stock has an average upside potential 2025 of . Most analysts recommend the aTyr Pharma, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.35 0.25
96.63% 27.74%
EBITDA Margin -14,908.57% -27,920.92%
3,364.55% 87.28%
Net Margin -20,357.71% -26,080.35%
1,644.04% 28.11%

7 Analysts have issued a sales forecast aTyr Pharma, Inc. 2024 . The average aTyr Pharma, Inc. sales estimate is

$253k
Unlock
. This is
57.14% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$500k 15.25%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $350k 96.63%
2024
$253k 27.74%
Unlock
2025
$5.3m 2,004.67%
Unlock
2026
$64.2m 1,106.92%
Unlock
2027
$206m 220.76%
Unlock
2028
$482m 134.09%
Unlock

1 Analyst has issued an EBITDA forecast aTyr Pharma, Inc. 2024 . The average aTyr Pharma, Inc. EBITDA estimate is

$-70.6m
Unlock
. This is
17.73% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-70.6m 17.73%
Unlock
, the lowest is
$-70.6m 17.73%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-52.2m 16.71%
2024
$-70.6m 35.30%
Unlock
2025
$-72.2m 2.27%
Unlock
2026
$51.8m 171.75%
Unlock
2027
$144m 177.99%
Unlock
2028
$483m 235.63%
Unlock

EBITDA Margin

2023 -14,908.57% 3,364.55%
2024
-27,920.92% 87.28%
Unlock
2025
-1,356.45% 95.14%
Unlock
2026
80.63% 105.94%
Unlock
2027
69.88% 13.33%
Unlock
2028
100.20% 43.39%
Unlock

2 aTyr Pharma, Inc. Analysts have issued a net profit forecast 2024. The average aTyr Pharma, Inc. net profit estimate is

$-66.0m
Unlock
. This is
4.39% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-60.6m 12.09%
Unlock
, the lowest is
$-71.3m 3.29%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-71.3m 41.25%
2024
$-66.0m 7.44%
Unlock
2025
$-55.3m 16.10%
Unlock
2026
$-33.0m 40.41%
Unlock
2027
$43.2m 231.06%
Unlock

Net Margin

2023 -20,357.71% 1,644.04%
2024
-26,080.35% 28.11%
Unlock
2025
-1,039.58% 96.01%
Unlock
2026
-51.33% 95.06%
Unlock
2027
20.97% 140.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.94 -0.87
41.25% 7.45%
P/E negative
EV/Sales 654.96

2 Analysts have issued a aTyr Pharma, Inc. forecast for earnings per share. The average aTyr Pharma, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.87
Unlock
. This is
4.40% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.80 12.09%
Unlock
, the lowest is
$-0.94 3.30%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.94 41.25%
2024
$-0.87 7.45%
Unlock
2025
$-0.73 16.09%
Unlock
2026
$-0.44 39.73%
Unlock
2027
$0.57 229.55%
Unlock

P/E ratio

Current -3.36 242.86%
2024
-3.49 3.87%
Unlock
2025
-4.16 19.20%
Unlock
2026
-6.99 68.03%
Unlock
2027
5.33 176.25%
Unlock

Based on analysts' sales estimates for 2024, the aTyr Pharma, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

654.96
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
911.27
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 280.69 11,795.42%
2024
654.96 133.34%
Unlock
2025
31.11 95.25%
Unlock
2026
2.58 91.71%
Unlock
2027
0.80 68.82%
Unlock
2028
0.34 57.29%
Unlock

P/S ratio

Current 390.54 5,827.19%
2024
911.27 133.33%
Unlock
2025
43.29 95.25%
Unlock
2026
3.59 91.71%
Unlock
2027
1.12 68.82%
Unlock
2028
0.48 57.28%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today